招银证券:给予和黄医药(00013.HK)“增持”评级 目标价35.67港元
来源:同花顺金融研究中心     时间:2023-08-02 14:03:51


(资料图片仅供参考)

招银证券8月2日发布公告。Maintain BUY. We are positive about the FDA/EMA approvals of fruquintinib in late2023. We revised our TP from HK$37.49to HK$35.67based on DCF valuation (WACC:10.25%, terminal growth rate:3.0%).

标签: